The Effect of Alpha Linolenic Acid Intake on Patients With Elevated Glycemic Status
NCT ID: NCT05053347
Last Updated: 2025-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
94 participants
INTERVENTIONAL
2022-07-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus
NCT00363233
Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?
NCT01698112
ALA on Glycemic Control in T2DM Participants
NCT02701894
Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Gestational Diabetic Patients
NCT01912170
Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients
NCT01857167
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flaxseed oil
Flaxseed oil capsule, 4.5 g/d (ALA 2.5 g/d)
Flaxseed oil capsule
The participants were asked to take flaxseed oil capsule 4.5 g/d (ALA 2.5g/d). The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Corn oil
Corn oil capsule, 4.5 g/d
Corn oil capsule
The participants were asked to take corn oil capsule 4.5 g/d. The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flaxseed oil capsule
The participants were asked to take flaxseed oil capsule 4.5 g/d (ALA 2.5g/d). The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Corn oil capsule
The participants were asked to take corn oil capsule 4.5 g/d. The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c 5.7-7.0%;
* Patients with previously diagnosed type 2 diabetes with stable drug hypoglycemic treatment and blood glucose controlled well.
Exclusion Criteria
* Suffering from severe metabolic disorders, malignancies, psychiatric conditions;
* undergoing insulin therapy, or antibiotic/probiotic use for more than three consecutive days in the last month.
* Daily cooking oil is flaxseed oil, rapeseed oil or other α -linolenic acid rich vegetable oil;
* Intake more than 20g walnuts per day or more than 100g fatty fish per week in the last month;
* Take nutritional supplements, such as fish oil capsules, perilla seed oil and flaxseed oil capsules, for nearly one month;
* Allergic to the content of intervention;
* Failure to eat the tested sample as prescribed and affect the efficacy or safety judgment.
30 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liegang Liu
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sinopharm Dongfeng General Hospital
Shiyan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JWY20210916
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.